Por favor, use este identificador para citar o enlazar este ítem:http://uvadoc.uva.es/handle/10324/44479
Título
Phenotypic modulation of cultured primary human aortic vascular smooth muscle cells by uremic serum
Autor
Año del Documento
2018
Editorial
Frontiers
Descripción
Producción Científica
Documento Fuente
Frontiers in Physiology, 2018, vol 9, n. 89. 14 p.
Abstract
Patients with chronic kidney disease (CKD) have a markedly increased incidence of cardiovascular disease (CVD). The high concentration of circulating uremic toxins and alterations in mineral metabolism and hormone levels produce vascular wall remodeling and significant vascular damage. Medial calcification is an early vascular event in CKD patients and is associated to apoptosis or necrosis and trans-differentiation of vascular smooth muscle cells (VSMC) to an osteogenic phenotype. VSMC obtained from bovine or rat aorta and cultured in the presence of increased inorganic phosphate (Pi) have been extensively used to study these processes. In this study we used human aortic VSMC primary cultures to compare the effects of increased Pi to treatment with serum obtained from uremic patients. Uremic serum induced calcification, trans-differentiation and phenotypic remodeling even with normal Pi levels. In spite of similar calcification kinetics, there were fundamental differences in osteochondrogenic marker expression and alkaline phosphatase induction between Pi and uremic serum-treated cells. Moreover, high Pi induced a dramatic decrease in cell viability, while uremic serum preserved it. In summary, our data suggests that primary cultures of human VSMC treated with serum from uremic patients provides a more informative model for the study of vascular calcification secondary to CKD.
Palabras Clave
Vascular calcification
Calcificación vascular
Uremia
Chronic kidney disease
Enfermedad renal crónica
Apoptosis
Human aorta
Arteria aorta
ISSN
1664-042X
Revisión por pares
SI
Patrocinador
Ministerio de Economía, Industria y Competitividad (grant BFU2016-78374-R, BFU2013-45867-R and BFU2016-75360-R)
Instituto de Salud Carlos III (grant PI13/01726)
Instituto de Salud Carlos III (grant PI13/01726)
Version del Editor
Propietario de los Derechos
© 2018 Frontiers
Idioma
eng
Tipo de versión
info:eu-repo/semantics/publishedVersion
Derechos
openAccess
Aparece en las colecciones
Files in questo item
La licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 Internacional